| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 04/11/2013 | US20130089538 Treating cancer by modulating mammalian sterile 20-like kinase 3 |
| 04/11/2013 | US20130089537 Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42 |
| 04/11/2013 | US20130089517 Homogeneous preparations of il-28 and il-29 |
| 04/11/2013 | US20130089515 Use of IL-12 and IL-12 Antagonists in the Treatment of Autoimmune Diseases |
| 04/11/2013 | US20130089512 Heteroaryl imidazolone derivatives as jak inhibitors |
| 04/11/2013 | US20130089497 ANTI-FcRH5 ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE |
| 04/11/2013 | CA2851244A1 Anti-human sema4a antibodies useful to treat disease |
| 04/11/2013 | CA2851220A1 Antibody specifically binding to epitope in sema domain of c-met |
| 04/11/2013 | CA2851135A1 Anti c-met antibody and uses thereof |
| 04/11/2013 | CA2850857A1 Liposome compositions comprising an adjuvant that activates or increases the activity of tlr2 and uses thereof |
| 04/11/2013 | CA2850745A1 Vaccine |
| 04/11/2013 | CA2850686A1 Phosphospecific antibodies recognising tau |
| 04/11/2013 | CA2848842A1 Ige anti -hmw-maa antibody |
| 04/10/2013 | EP2578684A1 Antagonists of ligands and uses thereof |
| 04/10/2013 | EP2578682A1 Antibody and use thereof |
| 04/10/2013 | EP2578598A1 Componds derived from normuramyldipeptide |
| 04/10/2013 | EP2578233A1 Therapeutic agent for pancreatic cancer |
| 04/10/2013 | EP2578232A1 Treatment drug for autoimmune diseases and allergic diseases |
| 04/10/2013 | EP2578231A1 Antitumor t cell response enhancer |
| 04/10/2013 | EP2578230A1 Removal of Tumor Cells from Intraoperative Autologous Blood Salvage |
| 04/10/2013 | EP2578229A1 Decreasing potential iatrogenic risks associated with vaccine antigens |
| 04/10/2013 | EP2576789A2 Novel modified live-attenuated vaccines (mlv) and subunit vaccines created by dna shuffling against porcine reproductive and respiratory syndrome virus (prrsv) |
| 04/10/2013 | EP2576772A1 Antigen-presenting modified naïve b cells for immune suppression and a method for producing said modified cells |
| 04/10/2013 | EP2576622A1 ANTIBODIES DIRECTED TO THE UNPROCESSED RECEPTOR TYROSINE KINASE c-MET |
| 04/10/2013 | EP2576621A1 Monoclonal antibodies against her2 |
| 04/10/2013 | EP2576620A1 Single -chain variable fragment anti-cd133 antibodies and uses thereof |
| 04/10/2013 | EP2576619A1 Humanised antigen binding proteins to myostatin6 |
| 04/10/2013 | EP2576618A1 Antibodies to human gdf8 |
| 04/10/2013 | EP2576617A2 MONOCLONAL ANTIBODIES TARGETING Aß OLIGOMERS |
| 04/10/2013 | EP2576616A2 Method for preparing antibodies having improved properties |
| 04/10/2013 | EP2576614A2 Class i mhc phosphopeptides for cancer immunotherapy and diagnosis |
| 04/10/2013 | EP2576613A1 Her-2 peptides and vaccines |
| 04/10/2013 | EP2576602A1 Chimeric momp antigen, method and use |
| 04/10/2013 | EP2576535A1 Combination cancer therapies with wortmannin analogs |
| 04/10/2013 | EP2575897A2 Crosslinking of proteins and other entities via conjugates of alpha-haloacetophenones, benzyl halides, quinones, and their derivatives |
| 04/10/2013 | EP2575885A1 Combination of anti-envelope antibodies and anti-receptor antibodies for the treatment and prevention of hcv infection |
| 04/10/2013 | EP2575884A2 Uses and compositions for treatment of hidradenitis suppurativa (hs) |
| 04/10/2013 | EP2575883A2 Treatment of inflammatory disorders |
| 04/10/2013 | EP2575882A2 Humanized monoclonal antibodies and methods of use |
| 04/10/2013 | EP2575881A1 Anti-cd160 specific antibodies for the treatment of eye disorders based on neoangiogenesis |
| 04/10/2013 | EP2575880A2 Monoclonal antibodies against her2 epitope |
| 04/10/2013 | EP2575879A1 Novel anti-cmet antibody |
| 04/10/2013 | EP2575878A1 Vaccines comprising cholesterol and cpg as sole adjuvant - carrier molecules |
| 04/10/2013 | EP2575877A1 Novel immunoadjuvant compounds and uses thereof |
| 04/10/2013 | EP2575876A1 Multivalent synthetic nanocarrier vaccines |
| 04/10/2013 | EP2575875A1 An immunogenic composition for treatment of hepatitis c, a method for preparing the composition and use thereof for treating hepatitis c |
| 04/10/2013 | EP2575874A1 Lactadherin-derived peptides as antiviral agents |
| 04/10/2013 | EP2575873A2 Concentration of vaccine antigens with lyophilization |
| 04/10/2013 | EP2575872A2 Concentration of influenza vaccine antigens without lyophilization |
| 04/10/2013 | EP2575871A1 Oral vaccine comprising an antigen and a toll-like receptor agonist |
| 04/10/2013 | EP2575870A2 Vaccine formulations |
| 04/10/2013 | EP2575869A1 Peptide particle formulation |
| 04/10/2013 | EP2575868A1 Ige ch3 peptide vaccine |
| 04/10/2013 | EP2575867A1 Novel interferon-alpha-producing bone marrow dendritic cells |
| 04/10/2013 | EP2575863A2 Use of the sparc microenvironment signature in the treatment of cancer |
| 04/10/2013 | EP2575857A2 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-trna synthetases |
| 04/10/2013 | EP2575856A2 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-trna synthetases |
| 04/10/2013 | EP2575850A1 Improved cancer therapy based on tumor associated antigens derived from cyclin d1 |
| 04/10/2013 | EP2575846A1 Insulin-like growth factor 1 receptor binding peptides |
| 04/10/2013 | EP2575832A1 Pharmaceutical product comprising mite allergen extract(s) and a method for the manufacture thereof |
| 04/10/2013 | EP2575824A2 Methods for the treatment and prevention of inflammatory diseases |
| 04/10/2013 | EP2575773A2 Synthetic nanocarrier combination vaccines |
| 04/10/2013 | EP2575764A2 Biodegradable lipids for the delivery of active agents |
| 04/10/2013 | EP2575761A1 Stable multi-dose compositions comprising an antibody and a preservative |
| 04/10/2013 | CN103038258A Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (LRP6) antibodies |
| 04/10/2013 | CN103038255A Novel anti-CD98 antibody and use thereof |
| 04/10/2013 | CN103038254A Antagonist anti-il-7 receptor antibodies and methods |
| 04/10/2013 | CN103037902A Methods and compositions for reducing parathyroid levels |
| 04/10/2013 | CN103037901A Cd36 inhibition to control obesity and insulin sensitivity |
| 04/10/2013 | CN103037900A Folate receptor 1 antibodies and immunoconjugates and uses thereof |
| 04/10/2013 | CN103037899A Compositions containing stable antibody |
| 04/10/2013 | CN103037898A Respiratory syncytial virus antigenic compositions and methods |
| 04/10/2013 | CN103037897A Lactadherin-derived peptides as antiviral agents |
| 04/10/2013 | CN103037896A The N-domain of carcinoembryonic antigen and compositions, methods and uses thereof |
| 04/10/2013 | CN103037864A Compositions and methods for the treatment of addiction, psychiatric disorders, and neurodegenerative disease |
| 04/10/2013 | CN103031279A 重组黄病毒疫苗 Recombinant flavivirus vaccines |
| 04/10/2013 | CN103031258A Novel mycoplasma hyopneumoniae bacterial strain and vaccine composition thereof |
| 04/10/2013 | CN103030695A Anti c-met humanized antibody and uses thereof |
| 04/10/2013 | CN103030694A Preparation method of yolk immunoglobulin for preventing and treating escherichia coli-induced diarrhea of piglets |
| 04/10/2013 | CN103030693A Neutralization molecule of high-pathogenicity avian influenza and preparation method thereof |
| 04/10/2013 | CN103028114A Nucleic acid vaccine, immunoadjuvant of nucleic acid vaccine, and preparation methods of nucleic acid vaccine and immunoadjuvan |
| 04/10/2013 | CN103028113A Varicella zoster virus vaccine |
| 04/10/2013 | CN103028112A Newcastle disease and infectious bronchitis bivalent live vaccine |
| 04/10/2013 | CN103028111A Eimeria acevulina immunity adjustment type polyvalent multi-epitope DNA (Deoxyribose Nucleic Acid) vaccine |
| 04/10/2013 | CN102321638B New porcine reproductive and respiratory syndrome virus ORF5 modified gene and application thereof |
| 04/10/2013 | CN102296052B Specific antigenic peptide of polyclonal antibody aiming at ppGalNAc-T13, and its preparation method and use |
| 04/10/2013 | CN102229671B Anti-IMMT anthropogenic Fab antibody and application thereof in preparing anti-liver cancer drugs |
| 04/10/2013 | CN102180969B Monoclonal antibody with liver cancer resisting activity and application thereof |
| 04/10/2013 | CN102105148B Therapeutic combination comprising an AURORA kinase inhibitor and antiproliferative agents |
| 04/10/2013 | CN102038948B Vaccine for controlling persistent infection of hepatitis B virus |
| 04/10/2013 | CN101967186B Encephalitis virus protein and code gene and application thereof |
| 04/10/2013 | CN101967185B Encephalitis virus protein as well as coding gene and application thereof |
| 04/10/2013 | CN101909655B Method of delivering an anti-cancer agent to a cell |
| 04/10/2013 | CN101897964B Medicament for preventing autoimmune disease |
| 04/10/2013 | CN101863978B Human source anti-rabies virus Fab antibody, cross linking method thereof with nanometer particles and application thereof |
| 04/10/2013 | CN101791404B Fish soaking vaccine immunity adjuvant and application and using method thereof |
| 04/10/2013 | CN101775375B Preparation method of recombinant adeno-associated viruses containing EB virus latent membrane protein 1 and 2 genes and application thereof |
| 04/10/2013 | CN101712935B Candida albicans toxicity related gene CaMSS11 and application thereof |
| 04/10/2013 | CN101711280B TEM8 peptides and vaccines comprising the same |
| 04/10/2013 | CN101415730B Compositions and methods of use for antibodies of c-Met |